The Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta trial (CREATE), published in 2006, was a randomized, controlled, clinical trial enrolling 603 patients to study the cardiovascular benefit of Epoetin Beta in anemic patients (Hb level 11–12.5 g/dL) with stages III-IV CKD (GFR 15–35 mL/minute/1.73 m2). The gene discussed is GSTM1; the disease is chronic kidney disease.